The Russian mRNA vaccine against cancer will be free for patients, said Academician of the Russian Academy of Sciences, Chief Oncologist of the Russian Ministry of Health, and General Director of the National Medical Research Center of Radiology Andrey Kaprin.

‘We are on stream as when the technology is established, we should be able to reach somewhere around 300 thousand rubles ($3 million), I mean for the state, for patients, of course, it should be free,’ TASS quotes him as saying on Radio Russia.

Earlier, the director of the N.N. Petrov National Medical Research Center of Oncology, chief oncologist of the Northwestern Federal District of Russia, Alexey Belyaev, spoke about the new mRNA vaccine and how it works.

The head of the Federal Medical and Biological Agency, Veronika Skvortsova, stated that the vaccine against cancer diseases could be used to treat patients starting in 2025.

Unfortunately, the beginning of the end for the scourge of cancer is confined to Russia and possible member nations o the BRICS Bloc regarded as Russian-friendly. There is unlikely to be availability for people of the unfriendly Western nations that sanction the Russian Federation.  

Director of the N.N. Petrov National Medical Research Center of Oncology, Doctor of Medical Sciences, Professor, Chief Oncologist of the Northwestern Federal District of Russia Alexey Belyaev spoke about the new mRNA vaccine and how it works.

According to the specialist, the mRNA vaccine is therapeutic, not prophylactic, and therefore it activates the immune system to fight the disease.

‘mRNA vaccines are a breakthrough because the Gamaleya Institute has created a platform for producing these vaccines. They take tumour tissue and obtain the code of antigens by which the body sees this tumour.

‘Then they synthesize these corresponding proteins in the laboratory and introduce them into the body on some carrier and activate the patient’s immune system to fight the tumor,’ he noted.

Alexey Belyaev also emphasized that the advantage of this vaccine is its personalization, that is, it is selected according to the antigens of a specific tumor of a specific patient, which is where its greatest effect lies.

Specialists from the Federal Medical and Biological Agency expect to begin using the cancer vaccine to treat patients starting in 2025.

This was reported by the head of the agency, Veronika Skvortsova. She said that the three-year research cycle on this vaccine is essentially complete.

‘Thanks to the fact that a law on the use of personalized drugs was passed this year, we hope to start using it in patients as early as next year,’ TASS quotes her as saying.

In August, Skvortsova said that scientific organizations of the FMBA are developing oncovaccines against a number of aggressive tumours. The vaccine against colorectal cancer, in particular, has already passed all preclinical studies and is ready for use in patients. PLEASE SHARE OUR STORIES